Tumori最新文献

{"title":"Prognostic value of CT-measured baseline tumor volume in nivolumab-treated metastatic renal cell carcinoma.","authors":"Seher Yıldız Tacar, Deniz Tural, Mustafa Orhan Nalbant, Maide Müreva, Rumeysa Çolak, Caner Kapar, Oğuz Altunok, Bekir Doğan, Ezgi Değerli, Mesut Yılmaz","doi":"10.1177/03008916261490843","DOIUrl":"https://doi.org/10.1177/03008916261490843","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the association between baseline metastatic tumor volume measured on computed tomography (CT) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC) receiving nivolumab as second line or later line therapy.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed 43 patients with mRCC treated with nivolumab between August 2013 and March 2022. Baseline metastatic tumor volume was measured on CT scans obtained within 30 days before treatment initiation. The cohort median (117 cm³) was used as an exploratory, data derived cut-off to define low- and high-volume groups. Progression free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier analysis and Cox proportional hazards models.</p><p><strong>Results: </strong>Median PFS and OS were 26.97 and 28.11 months, respectively. Median PFS was 40.62 months in the low-volume group and 9.74 months in the high-volume group (p=0.012), while median OS was 46.9 and 12.89 months, respectively (p=0.006). High tumor volume and multiple metastatic sites were associated with poorer survival outcomes. Baseline imbalances in IMDC risk classification and nivolumab treatment line were observed between groups.</p><p><strong>Conclusion: </strong>Higher baseline metastatic tumor volume was associated with poorer survival outcomes in patients with mRCC treated with nivolumab. CT-based tumor volumetry may provide complementary prognostic information; however, these exploratory findings require validation in larger, prospective cohorts.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261490843"},"PeriodicalIF":2.0,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149138419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond chemobrain: A stepwise approach to identifying cognitive impairment in non-CNS cancer survivors.","authors":"Martina Pulze, Mattia Losa, Silvia Buonopane, Paolo Alì, Stefano Caneva, Matteo Pardini","doi":"10.1177/03008916261489141","DOIUrl":"https://doi.org/10.1177/03008916261489141","url":null,"abstract":"<p><p>Cancer-related cognitive impairment (CRCI) is common in patients with non-central nervous system malignancies, but its identification remains difficult because symptoms are heterogeneous, may predate treatment, and are not captured by a single measure. This narrative review synthesizes evidence on epidemiology, clinical phenotype, risk factors, neuropsychological assessment, neuroimaging, and practical pathways for identifying CRCI in oncology care. Emerging literature highlights subjective-objective discordance and self-awareness as clinically relevant dimensions. Prevalence varies by timing and method, with higher estimates from self-report than from screening tools or formal batteries. Identification is more reliable when assessment combines patient-reported outcomes (PRO), brief objective screening, and focused neuropsychological testing within baseline vulnerability and concurrent symptom burden. Older age, lower cognitive reserve, pretreatment cognitive impairment, systemic illness, fatigue, insomnia, mood symptoms, pain, and medication effects are major modifiers. In clinical settings, neuroimaging is useful primarily for differential diagnosis: conventional brain MRI excludes competing neurologic disorders, while volumetric MRI, diffusion imaging, resting-state functional MRI, and [18F]FDG-PET currently provide group-level evidence rather than individual diagnostic signatures. At present, CRCI is best identified through a stepwise clinical strategy integrating PRO evaluation, objective testing, risk profiling, and selective imaging, considering individual patient modifiers rather than a single diagnostic test.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261489141"},"PeriodicalIF":2.0,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growth in oncology clinical trials and decline of independent research: Insights from the 22nd AIFA National Report on clinical trials.","authors":"Celeste Cagnazzo, Silvia Stacchiotti, Giuseppe Procopio","doi":"10.1177/03008916261491163","DOIUrl":"https://doi.org/10.1177/03008916261491163","url":null,"abstract":"<p><p>The 22nd National Report on Clinical Trials of Medicinal Products published by the Italian Medicines Agency (AIFA) in July 2026 highlights contrasting trends in Italian clinical research. In 2024, 669 prospective clinical trials were authorized, the highest number recorded in the last three years. Oncology and hemato-oncology remained the leading therapeutic area, accounting for 248 (37%) authorized trials and showing the largest absolute increase compared with 2023. Despite a stable overall number of authorized clinical trials, the composition of Italian clinical research is changing, with a progressive shift towards industry-sponsored and international studies and a decline in the relative contribution of non-commercial investigator-initiated trials (IITs). This decline is particularly relevant to oncology, a field historically supported by academic cooperative groups and independent research networks, especially in rare cancers and areas where IIT research has traditionally complemented commercially sponsored drug development. Several factors, including increasing regulatory, administrative, technological and organizational complexity, may contribute to the observed decline by disproportionately affecting academic sponsors. Strengthening Clinical Trial Units and investing in dedicated research professionals should therefore become a strategic priority. The future competitiveness of Italian oncology research should be measured not only by its ability to attract industry-sponsored trials, but also by its capacity to generate independent research addressing unmet clinical questions and needs.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261491163"},"PeriodicalIF":2.0,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149075889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of life in first-line trials for endometrial cancer: A systematic review.","authors":"Valentina Tuninetti, Alberto Farolfi, Simona Butticè, Chiara Casadei, Roberta Danese, Antonino Musolino, Giorgio Valabrega, Massimo Di Maio","doi":"10.1177/03008916261468178","DOIUrl":"https://doi.org/10.1177/03008916261468178","url":null,"abstract":"<p><strong>Objective: </strong>As treatment strategies evolve in advanced or metastatic endometrial cancer (EC), quality of life (QoL) has become a key parameter in evaluating therapeutic value. This systematic review summarizes QoL outcomes from pivotal trials that have shaped clinical practice in advanced EC.</p><p><strong>Methods: </strong>Data from phase II-III randomized trials of advanced or recurrent EC reporting patient-reported outcomes (PROs) were reviewed. Eligible studies assessed health-related QoL using validated instruments. The review focused on trials that met their primary endpoint and reported QoL or PROs in peer-reviewed publications and/or congress presentations. Data extraction and appraisal were conducted independently by the authors, and findings were synthesized narratively.</p><p><strong>Results: </strong>In the RUBY trial, dostarlimab plus chemotherapy prolonged time to deterioration and delayed permanent QoL decline in mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) patients. NRG-018 explored QoL in the mismatch repair-proficient (pMMR) cohort, with later planned time points still pending full publication. AtTEnd trial reported no clinically meaningful deterioration in global QoL with atezolizumab plus chemotherapy. In DUO-E, QoL was maintained with durvalumab-based strategies, with clinically meaningful physical functioning gains in the dMMR subgroup. In KEYNOTE-775, global QoL was broadly comparable between lenvatinib plus pembrolizumab and chemotherapy, although differences emerged in selected symptom domains.</p><p><strong>Conclusion: </strong>QoL provides a direct, patient-centered assessment of disease burden and treatment impact, complementing efficacy endpoints. However, QoL analyses remain inconsistently reported, delayed, and difficult to compare. Strengthening the integration and standardized reporting of PROs is essential to better define treatment value in advanced EC.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261468178"},"PeriodicalIF":2.0,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149081142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of infusion-related reactions to chemotherapy versus targeted therapy: A four-year experience at the Medical Day Hospital of the Fondazione IRCCS Istituto Nazionale Tumori Milano.","authors":"Gabriella Mariani, Valentino Ippocrates Redaelli, Chiara Cavalli, Federica Manoni, Katia Fiorella Dotti, Laura Anna Maria Ferrari","doi":"10.1177/03008916261478866","DOIUrl":"https://doi.org/10.1177/03008916261478866","url":null,"abstract":"<p><strong>Background: </strong>Infusion reactions (IRs) are a significant concern in oncology due to unpredictable onset and a lack of standardized management guidelines.</p><p><strong>Objectives: </strong>To compare the incidence, severity and management of IRs related to chemotherapy and targeted therapies in real-world practice, based on the experience of Medical Day Hospital at the Fondazione IRCCS Istituto Nazionale Tumori in Milan.</p><p><strong>Methods: </strong>A retrospective analysis of 73,057 non-investigational drug preparations (39,468 chemotherapies; 33,589 targeted therapies) was conducted between 2020 and 2023. The primary endpoint was the incidence of IRs per administration. Statistical comparison was performed using the Chi-square test.</p><p><strong>Results: </strong>A total of 646 IRs were observed (0.88%). The median age was 61 years (range 19-90), 75 % female and 25% male. The incidence was significantly higher for chemotherapy (1.17%) compared to targeted therapies (0.55%; p < 0.0001). The most problematic chemotherapies were paclitaxel (reaction risk 2.77%) and oxaliplatin (5.18%). For targeted therapies, rituximab (2.37%) and nivolumab (0.52%) showed the highest risk. Most reactions (97.4%) were mild (G1-G2) according to CTCAE 5.0.</p><p><strong>Conclusions: </strong>Chemotherapy remains associated with a significantly higher risk of IRs compared to targeted therapies. Although clinical presentations are similar, distinct pathophysiological mechanisms require tailored management and risk assessment.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261478866"},"PeriodicalIF":2.0,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149082320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and economic impact of community-based cancer care: Results from the S.M.A.R.T. Care Project in metastatic breast cancer patients.","authors":"Manuela Milani, Carla Strina, Marzia Alberio, Valeria Cervoni, Nicoletta Ziglioli, Donatella Caffi, Gianluca Vago, Pierfranco Conte, Gianni Amunni, Francesca Ferrè, Daniele Generali","doi":"10.1177/03008916261478403","DOIUrl":"https://doi.org/10.1177/03008916261478403","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the clinical and economic impact of shifting from hospital-based to community-based administration of oral, subcutaneous, and intramuscular anticancer therapies for patients with metastatic breast cancer (mBC).</p><p><strong>Methods: </strong>This prospective observational study enrolled 50 mBC patients receiving oral, subcutaneous, or intramuscular anticancer therapies in Cremona, Italy. After 12 weeks from starting the oncological treatments / first radiological evaluation (baseline), patients were transitioned from hospital-based (Day Hospital) to a community healthcare facility at the Croce Rossa Headquarter in Cremona. Quality of life was assessed using Functional Assessment of Cancer Therapy-Breast (FACT-B) and EORTC QLQ-C30 questionnaires at baseline, two months, and six months. Economic outcomes were assessed from the healthcare service perspective and included healthcare resource utilization (chair occupancy time, nursing time per patient, consumables per cycle), patient productivity loss, and total non-drug-related costs per treatment cycle; drug acquisition costs were excluded as they did not differ between the two care settings.</p><p><strong>Results: </strong>Mean FACT-B subscale scores improved significantly over six months: Social Well-Being (SWB) increased from 10.3 ± 2.0 at baseline to 14.8 ± 2.6 (p < 0.001), Emotional Well-Being (EWB) from 9.9 ± 2.1 to 11.2 ± 2.0 (p = 0.002), and Functional Well-Being (FWB) from 15.0 ± 3.0 to 16.9 ± 3.3 (p = 0.003). EORTC QLQ-C30 global health status improved from 40% to 70%. The territorial model reduced caregiver burden from 50% to 30% of visits, eliminating the need for caregiver work leave (from 52% to 20%), and decreased mean treatment duration from 180 ± 45 to 43 ± 18 minutes. The economic analysis showed an 85% reduction in chair occupancy time (3.2 ± 0.6 vs 0.48 ± 0.2 hours), a 76% reduction in nursing time per patient (180 ± 45 vs 43 ± 18 minutes), a 69% reduction in consumables cost per cycle (€42.50 ± 10.8 vs €13.18 ± 6.5), and a 65% reduction in patient productivity loss (€85.40 ± 24.3 vs €29.89 ± 12.7), translating into an approximately 80% reduction in total non-drug-related costs per cycle (€158.30 vs €31.66 per patient).</p><p><strong>Conclusions: </strong>Community-based administration of oral, subcutaneous, and intramuscular anticancer therapies in mBC patients significantly improves quality of life, reduces caregiver burden, and generates substantial economic savings while maintaining clinical safety. This reorganization model represents a sustainable and patient-centered approach to oncology care delivery.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261478403"},"PeriodicalIF":2.0,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149075640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Choriocarcinoma: diagnosis, treatment and management of a rare germ cell tumour. An update review\".","authors":"","doi":"10.1177/03008916261470142","DOIUrl":"https://doi.org/10.1177/03008916261470142","url":null,"abstract":"","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261470142"},"PeriodicalIF":2.0,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149040770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Composite clinical scores in real-world extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy.","authors":"Teresa Beninato, Giulia Stasi, Giulia Montelatici, Marta Brambilla, Laura Mazzeo, Mario Occhipinti, Marco Meazza Prina, Giulia Corrao, Arsela Prelaj, Claudia Proto, Paolo Ambrosini, Rebecca Romanò, Chiara Cavalli, Giuseppe Leone, Giovanni Leuzzi, Monica Ganzinelli, Stefano Natangelo, Marta De Ponti, Filippo M de Braud, Giuseppe Lo Russo","doi":"10.1177/03008916261457067","DOIUrl":"https://doi.org/10.1177/03008916261457067","url":null,"abstract":"<p><strong>Background: </strong>Composite scores such as Lung Immune Prognostic Index (LIPI), modified Glasgow Prognostic Score (mGPS), EPSILoN, Pan Immune-Inflammation Value (PIV) and Systemic Immune-Inflammation Index (SII) have shown prognostic value in solid tumors, but evidence in extensive-stage small-cell lung cancer (ES-SCLC) are limited.</p><p><strong>Methods: </strong>This monocentric retrospective/prospective observational study included 67 ES-SCLC patients treated with first-line chemo-immunotherapy. Baseline clinical and laboratory data were collected. LIPI, mGPS, and EPSILoN were calculated according to previously reported methodology; optimal cut-offs for SII and PIV were determined using maximally selected rank statistics. Survival outcomes were estimated through Kaplan-Meier method. Prognostic associations were evaluated through univariate and multivariate Cox proportional hazards models.</p><p><strong>Results: </strong>Median progression free survival (PFS) and overall survival (OS) in the study cohort were 4.8 and 11.3 months; 14.9% achieved long term survival (OS 24 months). Poor-risk categories of LIPI (PFS p<0.0001, OS p<0.0001), EPSILoN (PFS p=0.0012, OS p=0.0301), PIV (PFS p=0.0147, OS p=0.00543), and SII (PFS p=0.00016, OS p<0.0001) were strongly associated with inferior outcomes. In multivariate analysis, LIPI, EPSILoN and SII independently predicted both PFS and OS, whereas PIV retained significance for OS only. mGPS did not emerge as an independent prognostic marker.</p><p><strong>Conclusions: </strong>LIPI, SII and EPSILoN demonstrated significant prognostic value in ES-SCLC patients receiving first line chemo-immunotherapy, supporting their role in clinical stratification.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261457067"},"PeriodicalIF":2.0,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148971416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reducing the burden of active surveillance monitoring examinations in prostate cancer: Insights from real-world data to inform clinical practice.","authors":"Cristina Marenghi, Fabio Badenchini, Barbara Avuzzi, Mario Achille Catanzaro, Alessandra Casale, Alessia Casbarra, Laura Cattaneo, Melanie Claps, Valentina Guadalupi, Alberto Macchi, Antonella Messina, Sebastiano Nazzani, Barbara Noris Chiorda, Giuseppe Procopio, Silvia Stagni, Antonio Tesone, Tullio Torelli, Elena Verzoni, Sergio Villa, Riccardo Valdagni, Tiziana Rancati, Nicola Nicolai","doi":"10.1177/03008916261468121","DOIUrl":"https://doi.org/10.1177/03008916261468121","url":null,"abstract":"<p><strong>Background: </strong>Active surveillance (AS) is standard for early-stage prostate cancer, though intensive monitoring continues due to concerns about reclassification to Grade Group (GG) ⩾ 2. We hypothesized that simple and inexpensive clinical parameters could identify patients with indolent disease for whom less intensive monitoring is safe.</p><p><strong>Methods: </strong>We analyzed upgrading to ISUP Grade Group (GG) ⩾ 2 in a large cohort of low-risk prostate cancer (PCa) patients on AS. We used mixed-effects logistic regression to develop a model predicting non-upgrading at the next follow-up biopsy, based on routine time-updated clinical-pathological variables.</p><p><strong>Results: </strong>While annual reclassification persisted at a rate between 10.4% and 17.5% up to the 7th year, upgrades were predominantly GG2. Routine parameters powerfully stratified risk. Patients with a very unfavorable Prostate Specific Antigen (PSA) doubling time had a 40.5% upgrading rate versus 9.5% for those with a favorable value. The final model is based on baseline PSA density and number of positive cores, time-updated age and PSA doubling time category, detection of cancer in the last surveillance biopsy. The model showed moderate discrimination (0.73) in predicting non-upgrading.</p><p><strong>Conclusions: </strong>Many patients on AS have indolent disease but steady upgrading justifies monitoring. A model using simple, routine parameters and PSA doubling time can identify those at minimal risk of reclassification, enabling a safe reduction in biopsy intensity. This advocates for a risk-adaptive AS protocol, reserving advanced tools like MRI or biomarkers for the few higher-risk cases.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261468121"},"PeriodicalIF":2.0,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148814209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival of carcinoid lung neuroendocrine tumours after surgical resection: A retrospective audit of 633 cases over 26 years.","authors":"Mohamed Mortagy, Ker Shiong Tan, Marie Line El Asmar, Daisuke Nonaka, Saoirse Dolly, Rajaventhan Srirajaskanthan, Dominique Clement, Andrea Bille, Juliet King, Akshay Patel, John Ramage","doi":"10.1177/03008916261472659","DOIUrl":"https://doi.org/10.1177/03008916261472659","url":null,"abstract":"<p><strong>Background: </strong>Optimal postoperative follow-up for lung neuroendocrine tumours (L-NET) and surgical resection approaches remain debated. This audit aimed to benchmark long-term outcomes after L-NET surgery at a high-volume centre, identify prognostic factors, and estimate follow-up duration.</p><p><strong>Methods: </strong>This was a retrospective audit of 633 L-NET resections at a high-volume centre (1997-2023). Kaplan-Meier plots for overall survival (OS) were generated. Cox regression was used to identify the factors affecting OS. Expected survival was generated by matching age, sex, and year of surgery to national life tables.</p><p><strong>Results: </strong>Median age was 63 years; 66.8% were female; 78.2% had typical morphology; 78.2% were stage 1; and lobectomy predominated (83.7%). Ten-year OS was 80.4% for all cases and 82.7%, 84.5%, 58.9%, and 67.0% for lobectomy, pneumonectomy, segmentectomy, and wedge resection, respectively. Actual OS overlapped at ~220 months for all cases. Multivariable analysis showed that worse all-cause mortality was associated with advanced age (aHR 1.08) and lymphovascular invasion (aHR 2.38), but not procedure type.</p><p><strong>Conclusions: </strong>This audit provides valuable insights into the benefits and risks of surgery for L-NET at our centre. It identifies risk factors for increased all-cause mortality. It provides data on follow-up, which can inform local case selection, guidelines and policies at our centre.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261472659"},"PeriodicalIF":2.0,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148798456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}